| Ticker: CCVD | 13900 Alton Parkway, Suite 122 | |
| Exchange: NASDAQ-National Market | Irvine, California 92718 | |
| Industry: Manufacturing | (714) 457-9546 |
| Type of Shares: | Common Shares | Filing Date: | 5/6/96 | |
| U.S. Shares: | 3,400,000 | Offer Date: | 6/19/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $11.00 - $13.00 | |
| Primary Shares: | 3,400,000 | Offer Price: | $12.00 | |
| Secondary Shares: | 0 | Gross Spread: | $0.84 | |
| Offering Amount: | $40,800,000 | Selling: | $0.50 | |
| Expenses: | $770,000 | Reallowance: | $0.10 | |
| Shares Out After: | 8,262,500 | |||
| Spin out parent firm: | EndoSonics Corporation | |||
| Manager | Tier | Phone |
| Volpe, Welty & Company | Lead Manager | (415) 956-8120 |
| Vector Securities International, Inc. | Co-manager | (708) 940-1970 |
| Wessels, Arnold & Henderson | Co-manager | (612) 373-6121 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $4.10 | $2.03 | $0.41 | Assets: | $11.77 |
| Net Income: | -$2.87 | -$0.38 | -$0.63 | Liabilities: | $5.22 |
| EPS: | -$0.65 | -$0.08 | -$0.14 | Equity: | $6.55 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company designs, develops, manufactures and markets catheters used to treat certain vascular diseases. The company's catheters are used in conjunction with angioplasty and other interventional procedures such as vascular stenting and drug delivery. The company's proprietary FOCAL and Multiple Microporous Membrane technologies enable physicians to deliver therapeutic radial force, stents, drugs or contrast media accurately and effectively to the treatment site, and also allow the perfusion of blood during an interventional procedure. The company believes that the combination of these technologies on a multiple-purpose catheter enables physicians to effectively perform challenging interventional procedures, resulting in improved treatment outcomes and lower costs. The company has five issued and four allowed U.S. patents covering certain aspects of its catheter technologies. |
| Use of Proceeds |
| The proceeds from the offering will be used for product development, capital expenditures, clinical trials and studies, working capital, direct sales and marketing and repayment of debt owed to Endosonics. |
©1996 IPO Data Systems, Inc. - All rights reserved.